Belzutifan (MK-6482) Hepatic Impairment Study (MK-6482-020)
Status:
Not yet recruiting
Trial end date:
2022-09-28
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to compare the plasma pharmacokinetics (PK) of
belzutifan (MK-6482) following a single oral 120 mg dose of belzutifan in participants with
moderate hepatic impairment to that of healthy matched control participants. This study will
also evaluate the safety and tolerability of a single oral 120 mg dose of belzutifan in
participants with moderate hepatic impairment.